Education
About Us
Working with TipRanks
Follow Us
Niagen Bioscience (NAGE)
NASDAQ:NAGE
NAGE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.18 - $14.69
Previous CloseN/A
VolumeN/A
Average Volume (3M)848.05K
Market Cap
$778.39M
Enterprise Value$1.19B
Total Cash (Recent Filing)$60.32M
Total Debt (Recent Filing)$3.29M
Price to Earnings (P/E)45.5
Beta0.98
Next Earnings
Oct 29, 2025EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding79,752,960
10 Day Avg. Volume858,317
30 Day Avg. Volume848,050
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.52
Enterprise Value/Revenue10.19
Enterprise Value/Gross Profit16.02
Enterprise Value/Ebitda65.44
Forecast
1Y Price Target
$15.55Price Target Upside57.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical TrialsNiagen's proprietary molecules are undergoing multiple clinical trials for various rare diseases and pharmaceutical applications that could further unlock additional value.
Financial PerformanceNiagen Bioscience's revenue and earnings have exceeded expectations, leading to an increased price target.
Product InnovationNiagen Bioscience continues to see growing consumer interest around boosting NAD+ levels to help with healthy aging and has been innovating ways to help consumers meet their needs.
Bears Say
Legal RisksRisks include slower-than-projected U.S. sales growth, unfavorable clinical data, and adverse legal decisions.
Sales GrowthRisks to consider include slower-than-projected sales growth in the U.S. and potential adverse legal or geopolitical factors.
Niagen Bioscience News
NAGE FAQ
What was Niagen Bioscience’s price range in the past 12 months?
Niagen Bioscience lowest stock price was $3.18 and its highest was $14.69 in the past 12 months.
What is Niagen Bioscience’s market cap?
Niagen Bioscience’s market cap is $778.39M.
When is Niagen Bioscience’s upcoming earnings report date?
Niagen Bioscience’s upcoming earnings report date is Oct 29, 2025 which is in 28 days.
How were Niagen Bioscience’s earnings last quarter?
Niagen Bioscience released its earnings results on Aug 06, 2025. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.009 by $0.031.
Is Niagen Bioscience overvalued?
According to Wall Street analysts Niagen Bioscience’s price is currently Undervalued.
Does Niagen Bioscience pay dividends?
Niagen Bioscience does not currently pay dividends.
What is Niagen Bioscience’s EPS estimate?
Niagen Bioscience’s EPS estimate is 0.02.
How many shares outstanding does Niagen Bioscience have?
Niagen Bioscience has 79,752,960 shares outstanding.
What happened to Niagen Bioscience’s price movement after its last earnings report?
Niagen Bioscience reported an EPS of $0.04 in its last earnings report, beating expectations of $0.009. Following the earnings report the stock price went up 2.234%.
Which hedge fund is a major shareholder of Niagen Bioscience?
Currently, no hedge funds are holding shares in NAGE
Niagen Bioscience Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.55 (57.07% Upside)
$15.55 (57.07% Upside)
Blogger Sentiment
Bullish
NAGE Sentiment 75%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 52.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
160.52%
12-Months-Change
Fundamentals
Return on Equity
37.36%
Trailing 12-Months
Asset Growth
69.38%
Trailing 12-Months
Company Description
Niagen Bioscience
Niagen Bioscience (NAGE) is a biotechnology company focused on the research, development, and commercialization of innovative health and wellness products. The company operates primarily within the nutraceuticals sector, specializing in the production of nicotinamide riboside (NR), a precursor to NAD+ (nicotinamide adenine dinucleotide). NR is associated with various health benefits, including cellular energy production, anti-aging effects, and improved metabolic health. Niagen's core products include dietary supplements aimed at enhancing cellular health and longevity, catering to a growing consumer demand for wellness-oriented solutions.
NAGE Company Deck
NAGE Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Niagen Bioscience presented a robust performance with significant revenue growth, increased net income, and cash generation. The expansion of Niagen Plus and a strengthened patent portfolio were key positive aspects. However, the company faces regulatory challenges and market misconceptions that require ongoing attention.View all NAGE earnings summariesNAGE Stock 12 Month Forecast
Average Price Target
$15.55
▲(57.07% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Kura Oncology
―
Vir Biotechnology
―
Fortrea Holdings Inc.
―
Septerna, Inc.
―
Ownership Overview
4.99% Insiders
7.57% Mutual Funds
7.23% Other Institutional Investors
72.08% Public Companies and
Individual Investors